MannKind | MNKD - Bruttoergebnis Vom Umsatz





Bruttoergebnis Vom Umsatz Veränderung Datum
Adma Biologics USD 88.82M 13.19M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 68.33M 9.98M 2026-03
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Novavax USD 125.04M 76.09M 2025-12
Novo Nordisk DKK 64.01B 1.19B 2025-06
Pfizer USD 11.04B 1.24B 2026-03
Sanofi EUR 8.45B 1.31B 2025-12
Xencor USD 21M 22.61M 2025-09